WuXi Biologics (Cayman) stock
Price history
+44.44% over the period1 year: from $32.36 (November 17, 2025) to $46.74 (November 16, 2026), +44.44%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | $46.74 |
| October 30, 2026 | $44.48 |
| September 30, 2026 | $56.05 |
| August 31, 2026 | $48.84 |
| July 31, 2026 | $38.74 |
| June 30, 2026 | $34.60 |
| May 29, 2026 | $33.34 |
| April 30, 2026 | $33.04 |
| March 31, 2026 | $33.02 |
| February 27, 2026 | $40.22 |
| January 30, 2026 | $37.00 |
| December 31, 2025 | $31.44 |
| November 28, 2025 | $31.16 |
| November 17, 2025 | $32.36 |
At a glance
The company
Provides end-to-end biologics discovery, development, and manufacturing services through contract research and manufacturing platforms
Latest results
Quarter to June 30, 2026 · EPS ¥0.58
TickerLandia's take on WuXi Biologics (Cayman)
- Cheaper than similar companies: trailing 12-month P/E 35 vs 40 (−13%) in a group of 8.
- Strong point: Earnings stability (87/100 in its group). Weak point: Growth (44/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−19.41% from the 52-week high
Analysts · 27 analysts
Average target$60.21+28.82% vs. price
Buy 23 · Hold 4 · Sell 0 · Strong buy
TickerLandia Fingerprint: WuXi Biologics (Cayman)
Compared with similar companies: very high earnings stability and very strong momentum.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.
Pricelow38
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 35.1 45 Forward P/E 21.4 37 Price/book 3.40 22 Price/sales 8.14 41 EV/EBITDA 20.8 43 Profitabilityaverage56
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 32.4% 81 Net margin 21.2% 63 ROE 11.4% 52 Gross margin 47.5% 19 ROA 7.6% 64 Earnings stabilityvery high87
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.5% 91 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 84 Growthaverage44
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +18.40% 46 Earnings growth (year over year) +4.30% 54 Average revenue growth (3 years) +12.59% 32 Financial strengthhigh63
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.05 64 Current ratio 3.32 50 Interest coverage 46.5 69 Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.77 70 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery strong82
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +9.84% 66 1-year return +35.56% 78 Relative strength (6 months) +54.10% 97 Distance from 200-day average +15.76% 87 Riskhigh62
How much the price swings.
Metric Value Position in group Volatility (60 days) 51.4% 72 Beta (1 year) 1.27 76 Maximum drawdown (12 months) 28.7% 38
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
WuXi Biologics (Cayman) is cheaper than similar companies
WuXi Biologics (Cayman)'s P/E (trailing 12 months): 35.1, −13% against the median of a group of 8 similar companies (40.2).
Compared with 8 similar companies
| Metric | WuXi Biologics (Cayman) | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 35.1 | Middle | |
| Forward P/E | 21.4 | Low | |
| Operating margin | 32.4% | High | |
| ROE | 11.4% | Middle | |
| Debt/equity | 0.05 | Low |
Grey band: the middle half of the group; tick: the median; dot: WuXi Biologics (Cayman). All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
¥11.79B
Latest quarter · Q2 2026
Net income
¥2.44B
Latest quarter · Q2 2026
Quarterly net margin
20.7%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $192.4B
- P/E
- 35.1
- EPS
- $1.33
- Volume
- 28.51M
- Daily trading
- €177.87M
- Dividend yield
- 0.00%
How WuXi Biologics (Cayman) is changing
All resultsRevenue grew 31.2% a year on average over the last 5 years
Operating margin rose from 28.5% to 30.5%
Less cash than profit: free cash flow equal to 39% of net income
Returns
WuXi Biologics (Cayman) returns
$1,000 invested in WuXi Biologics (Cayman) 5 years ago, on November 16, 2021, would be worth $424 today: −57.59% in total, −15.77% per year. This is the price return only: dividends are excluded.
| Period | WuXi Biologics (Cayman) | Hang Seng | $1,000 becomes |
|---|---|---|---|
| 1 month | −3.03% | −1.79% | $970 |
| 6 months | +38.78% | −8.96% | $1,388 |
| Year to date | +48.66% | −7.32% | $1,487 |
| 1 year | +44.44% | −9.97% | $1,444 |
| 3 years | −2.12% | +33.20% | $979 |
| 5 years | −57.59% | −7.62% | $424 |
Over the last 6 months it has done better than 90% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
WuXi Biologics (Cayman): technical analysis
WuXi Biologics (Cayman) shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 67.9% below its all-time closing high ($145.60, June 28, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 45
- Between 30 and 70
- vs 200-session average
- +15.65%
Support and resistance
Price areas where WuXi Biologics (Cayman) has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$48.30+3.34%2 touches, last on August 31, 2026
- Last price$46.74
- Support$43.24−7.49%3 touches, last on November 3, 2026
- Support$40.60−13.14%3 touches, last on July 16, 2026
- Support$36.91−21.02%3 touches, last on July 30, 2026
Volatility and risk
Over the last year it has moved more than the Hang Seng.
- Beta (1 year) vs Hang Seng
- 1.26
- Volatility (60 sessions, annualised)
- 50.8%
- Largest fall in the last year
- −28.74%
Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
WuXi Biologics (Cayman): seasonality
Average monthly price change over 10 years
Over the last 10 years, the strongest month for WuXi Biologics (Cayman) has been July: +8.53% on average, positive in 7 years out of 10. The weakest has been October: −5.09% on average, positive in 4 years out of 10. November, the current month, has been positive in 4 years out of 9 (+2.56% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +5.31% | +6.96% | 7 of 9 |
| February | +0.73% | +1.21% | 5 of 9 |
| March | −0.20% | +1.25% | 5 of 9 |
| April | −0.05% | −3.92% | 4 of 9 |
| May | +0.25% | +0.66% | 5 of 9 |
| June | +6.16% | +3.59% | 6 of 9 |
| July | +8.53% | +12.26% | 7 of 10 |
| August | +5.33% | +0.86% | 6 of 10 |
| September | +6.55% | +2.80% | 7 of 10 |
| October | −5.09% | −6.52% | 4 of 10 |
| November | +2.56% | −4.38% | 4 of 9 |
| December | +0.83% | +0.90% | 5 of 9 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
WuXi Biologics (Cayman) and its competitors
The company is best known for platforms such as WuXiBody, SDArBodY, WuXiUP and WuXiHigh, which it applies across biologics work. Its activities run from early discovery and the preparation of investigational new drug filings through process development and commercial-scale production, and also include vaccine contract manufacturing, clinical and manufacturing services, and the development, production and distribution of biotechnological products. Operations are organised in two segments, Biologics and XDC, and the company serves customers in China, North America, Europe, Singapore, Japan, South Korea, Australia and Brazil.
- Headquarters
- Wuxi, China
- Employees
- 14,705
- Founded
- 2014
- Chief executive
- Zhisheng Chen
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| WuXi Biologics (Cayman)2269 | $24.52B | 32.4% | 35.1 | +38.78% |
| Innovent Biologics1801 | $18.84B | 7.4% | 111.5 | +2.32% |
| Celltrion068270 | $36.68B | 31.6% | 26.4 | +19.29% |
| Sichuan Kelun-Biotech Biopharmaceutical6990 | $13.65B | -0.2% | — | +0.78% |
| Sino Biopharmaceutical1177 | $12.49B | 28.2% | 36.7 | +2.23% |
| Samsung Biologics207940 | $49.13B | 45.5% | 33.4 | +0.28% |
Same industry or related industries, similar size. Compare WuXi Biologics (Cayman) with its competitors · Full profile
